[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Erbe USA Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":120},{"warningLetters":4,"total":119},[5,34,57,78,97],{"id":6,"raw":7,"subject":12,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":28,"issuing_office":29,"recipient_name":30,"body_fetched_at":31,"delivery_method":32,"recipient_title":20,"reference_number":20,"action_taken_date":33,"medical_device_id":20,"response_letter_date":20},1513,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2024-04-16T13:20:00Z\">04\u002F16\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-11-22T05:00:00Z\">11\u002F22\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feuro-usa-inc-666173-11222023\">Euro USA Inc\u003C\u002Fa>"," Division of Human and Animal Food Operations East V","Seafood HACCP\u002FCGMP for Foods\u002FAdulterated\u002FInsanitary Conditions","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feuro-usa-inc-666173-09172024\">\u003Ctime datetime=\"2024-09-23T04:00:00Z\">09\u002F23\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Joseph O’Donnell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Euro USA Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4481 Johnston Parkway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cleveland\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>44128\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East V\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER 666173\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 22, 2023\u003C\u002Fp>\n\n\u003Cp>Mr. Joseph O’Donnell, Chief Executive Officer\u003Cbr>\nEuro USA, Inc.\u003Cbr>\n4481 Johnston Parkway\u003Cbr>\nCleveland, Ohio 44128\u003C\u002Fp>\n\n\u003Cp>Dear Mr. O’Donnell:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your seafood processing facility located at 4481 Johnston Parkway, Cleveland Ohio from July 10 to July 25, 2023. We found that you have serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 123, and the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). In accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your fish and fishery products are adulterated, in that they have been prepared, packed, or held under insanitary conditions whereby it may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation and the Fish and Fisheries Products Hazards &amp; Controls Guidance through links in FDA's home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, the FDA investigator issued your facility a Form FDA 483, Inspectional Observations. You provided a written response to the inspection on August 11, 2023, which included corrective actions taken by your firm. We have reviewed the documentation and continue to have serious concerns with your HACCP program.\u003C\u002Fp>\n\n\u003Cp>Your significant deviations are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You must have a HACCP plan that, at a minimum, lists the critical limits that must be met, to comply with 21 CFR 123.6 (c)(3). A critical limit is defined in 21 CFR 123.3 (c) as \"the maximum or minimum value to which a physical, biological, or chemical parameter must be controlled at a critical control point to prevent, eliminate, or reduce to an acceptable level the occurrence of the identified food safety hazard.\" However, your firm’s HACCP plans for Combined Molluscan Shellfish that includes your shucked, raw scallops in cans, Pasteurized Crabmeat and Scombroid Fish lists critical limits that are inadequate to control the hazards of Clostridium botulinum, pathogenic growth and toxin formation and histamine formation.\u003C\u002Fp>\n\n\u003Cp>a. At the storage critical control point for your Combined Molluscan Shellfish, which includes reduced oxygen packaged shucked raw scallops in cans, the listed critical limit is “Storage cooler temperature not to exceed \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, a critical limit of \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>is necessary to control C. botulinum growth and toxin formation\u003C\u002Fp>\n\n\u003Cp>b. At the storage critical control point for your Pasteurized Crabmeat HACCP, the listed critical limit of “Storage cooler temperature should not exceed \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>for over \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, many of the cooler temperatures exceeded this critical limit in June and July 2023. Most notably, the temperature range was \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;from July 2-8, 2023. In addition, your critical limit should ensure the products are \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Furthermore, our investigator reviewed your continuous monitoring system (CMS) records for your seafood storage cooler. The CMS data records from May 20 to July 10, 2023, revealed your seafood storage cooler temperatures ranged from \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>for entire days. Additionally, employees used infrared thermometer (IR) guns to monitor the same storage cooler temperatures and for the same time span, the IR temperature recordings were logged at \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>c. The receiving CCP for your Combined Molluscan Shellfish HACCP plan that includes your reduced oxygen packaged shucked raw, scallops in cans, lists a critical limit that fails to ensure the products were held at adequate temperatures continuously during transit to your facility \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>d. The receiving CCP for your Scombroid fish HACCP plan, lists a critical limit that is not adequate to control histamine formation. The critical limit indicates you may receive scombroid fish with gel packs. If so, FDA recommends internal temperatures of a representative number of fish be taken at receiving. Your written response indicated that you are revising your HACCP plans to reflect the correct CCP, and seafood staff have been trained on new procedures. We find your response inadequate in that you did not provide evidence\u002Fdocumentation to demonstrate your corrective actions or that employee training was performed.\u003C\u002Fp>\n\n\u003Cp>2. You must implement the monitoring procedures and frequency that you have listed in your HACCP plan, to comply with 21 CFR 123.6(b), (c)(4). However, your firm did not follow monitoring and verification procedures for your Combined Molluscan Shellfish, Scombroid Fish and Pasteurized Crabmeat HACCP plans. Specifically,\u003C\u002Fp>\n\n\u003Cp>a. The monitoring procedure at the storage critical control point (CCP) for your Scombroid fish lists checking the adequacy of ice “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. However, your firm operates \u003Cstrong>(b)(4)\u003C\u002Fstrong>. According to your Daily Seafood Sanitation Reports on June 3, 6, 13, 17, 18, 20, 24, and 25, 2023 and July 4, 8, and 9, 2023, the adequacy of ice was \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On June 11 and July 1-3, 2023, the adequacy of ice was not checked at all. Furthermore, the monitoring procedures don’t include taking the internal temperatures of fish to ensure the critical limit is met. The monitoring procedures don’t require a representative number of containers to be examined and the approximate number of containers in the cooler.\u003C\u002Fp>\n\n\u003Cp>Your written response indicated that your HACCP plans are under review and will be revised. Additionally, your response indicated that employees were trained on proper monitoring procedures; however, a new HACCP plan hasn’t been implemented yet, nor was evidence provided to document employee training was performed. This response is inadequate in that corrective actions have not been taken or implemented. You also failed to offer a timeframe on when these revisions would be completed.\u003C\u002Fp>\n\n\u003Cp>3. You must take appropriate corrective actions when a deviation from a critical limit occurs, to comply with 21 CFR 123.7(a). However, your corrective actions were not appropriate to control your hazards of pathogenic bacteria growth, toxin formation and \u003Cem>C. botulinum\u003C\u002Fem> toxin formation when your cooler temperatures for the storage of Pasteurized Crabmeat and your shucked shellfish meat deviated from your listed critical limits of “Storage cooler temperature should not exceed \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>for over \u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “Storge cooler temperature not to exceed&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, respectively.\u003C\u002Fp>\n\n\u003Cp>Furthermore, your trained Seafood HACCP employee reviewed your CMS records that revealed critical limit deviations and failed to evaluate the product or conduct any type of corrective actions.\u003C\u002Fp>\n\n\u003Cp>Your written response indicated that employees were trained on the importance of performing necessary corrective actions; however, you failed to provide evidence that employee training was performed.\u003C\u002Fp>\n\n\u003Cp>4. Your HACCP plans include corrective action plans that are not in accordance with 21 CFR 123.7(b) to ensure affected product is not entered into commerce and the cause of the deviation was corrected as required by 21 CFR 123.6(c)(5). Specifically,\u003C\u002Fp>\n\n\u003Cp>a. The CCP of cooler storage of fresh shucked shellfish meat for you Combined Molluscan Shellfish and Pasteurized Crabmeat HACCP plans are inadequate to control Clostridium botulinum growth and toxin formation. Your HACCP plans do not list corrective actions on evaluating the cumulative time and the ambient cooler temperature exposures of the affected product, rejecting the lot or diverting to a non-food use.\u003C\u002Fp>\n\n\u003Cp>b. The CCP’s of receiving and Finished Product Storage in the Scombroid Fish HACCP plan are inadequate to control histamine formation. Taking the internal product temperature alone at receiving does not control the hazard. Additionally, waiting until the finished product storage cooler temperature is above \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>for more than \u003Cstrong>(b)(4)\u003C\u002Fstrong>, checking the adequacy of ice and product temperature does not control the hazard. Furthermore, the HACCP plan doesn’t document chilling, holding, rejecting or diverting the lot to non-food use.\u003C\u002Fp>\n\n\u003Cp>Your written response indicated that your HACCP plans are under review. This response is inadequate in that corrective actions have not been taken or implemented. Additionally, you failed to offer a timeframe on when these revisions would be completed.\u003C\u002Fp>\n\n\u003Cp>5. You must monitor sanitation conditions and practices during processing with sufficient frequency to ensure compliance with current good manufacturing practice requirements in 21 CFR 117, Subpart B (CGMPs) to comply with 21 CFR 123.11 (b). However, your firm did not monitor for the adequacy of key areas of sanitation \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>on June 3, 9, 13, 17, 18, 20, 24, 25 and July 4, 8 and 9, 2023. Additionally, you failed to check the adequacy of any key areas of sanitation at all on June 11 and July 1-3, 2023.\u003C\u002Fp>\n\n\u003Cp>Your written response indicated that employees were trained to check and record sanitation conditions and practices \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>per shift; however, you failed to provide evidence that employee training was performed or adequately completed “Daily Seafood CCP and Sanitation Report” forms.\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. You should take prompt action to address the violations noted in this letter. Failure to promptly address these violations may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. Please send your reply to the Food and Drug Administration, Attention: Allison Hunter, Compliance Officer, 550 Main Street, Suite 4-930, Cincinnati, Ohio 45202. If you prefer to send your response electronically, please email it to ORAHAFEAST5FirmResponses@fda.hhs.gov. If you have any questions regarding this letter, please contact Allison C. Hunter, Compliance Officer, at Allison.hunter@fda.hhs.gov or (513) 322-0629.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Steven B. Barber\u003Cbr>\nDirector, Division V\u003Cbr>\nOffice of Human and Animal Foods Operations-East\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Joseph O’Donnell\n\nRecipient Title\n\nChief Executive Officer\n\nEuro USA Inc\n\n4481 Johnston Parkway\n\nCleveland, OH 44128\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East V\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER 666173\n\nNovember 22, 2023\n\nMr. Joseph O’Donnell, Chief Executive Officer\n\nEuro USA, Inc.\n\n4481 Johnston Parkway\n\nCleveland, Ohio 44128\n\nDear Mr. O’Donnell:\n\nThe United States Food and Drug Administration (FDA) inspected your seafood processing facility located at 4481 Johnston Parkway, Cleveland Ohio from July 10 to July 25, 2023. We found that you have serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 123, and the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). In accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your fish and fishery products are adulterated, in that they have been prepared, packed, or held under insanitary conditions whereby it may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation and the Fish and Fisheries Products Hazards & Controls Guidance through links in FDA's home page at www.fda.gov.\n\nAt the conclusion of the inspection, the FDA investigator issued your facility a Form FDA 483, Inspectional Observations. You provided a written response to the inspection on August 11, 2023, which included corrective actions taken by your firm. We have reviewed the documentation and continue to have serious concerns with your HACCP program.\n\nYour significant deviations are as follows:\n\n1. You must have a HACCP plan that, at a minimum, lists the critical limits that must be met, to comply with 21 CFR 123.6 (c)(3). A critical limit is defined in 21 CFR 123.3 (c) as \"the maximum or minimum value to which a physical, biological, or chemical parameter must be controlled at a critical control point to prevent, eliminate, or reduce to an acceptable level the occurrence of the identified food safety hazard.\" However, your firm’s HACCP plans for Combined Molluscan Shellfish that includes your shucked, raw scallops in cans, Pasteurized Crabmeat and Scombroid Fish lists critical limits that are inadequate to control the hazards of Clostridium botulinum, pathogenic growth and toxin formation and histamine formation.\n\na. At the storage critical control point for your Combined Molluscan Shellfish, which includes reduced oxygen packaged shucked raw scallops in cans, the listed critical limit is “Storage cooler temperature not to exceed (b)(4). However, a critical limit of (b)(4) is necessary to control C. botulinum growth and toxin formation\n\nb. At the storage critical control point for your Pasteurized Crabmeat HACCP, the listed critical limit of “Storage cooler temperature should not exceed (b)(4) for over (b)(4). However, many of the cooler temperatures exceeded this critical limit in June and July 2023. Most notably, the temperature range was (b)(4) from July 2-8, 2023. In addition, your critical limit should ensure the products are (b)(4).\n\nFurthermore, our investigator reviewed your continuous monitoring system (CMS) records for your seafood storage cooler. The CMS data records from May 20 to July 10, 2023, revealed your seafood storage cooler temperatures ranged from (b)(4) for entire days. Additionally, employees used infrared thermometer (IR) guns to monitor the same storage cooler temperatures and for the same time span, the IR temperature recordings were logged at (b)(4).\n\nc. The receiving CCP for your Combined Molluscan Shellfish HACCP plan that includes your reduced oxygen packaged shucked raw, scallops in cans, lists a critical limit that fails to ensure the products were held at adequate temperatures continuously during transit to your facility (b)(4).\n\nd. The receiving CCP for your Scombroid fish HACCP plan, lists a critical limit that is not adequate to control histamine formation. The critical limit indicates you may receive scombroid fish with gel packs. If so, FDA recommends internal temperatures of a representative number of fish be taken at receiving. Your written response indicated that you are revising your HACCP plans to reflect the correct CCP, and seafood staff have been trained on new procedures. We find your response inadequate in that you did not provide evidence\u002Fdocumentation to demonstrate your corrective actions or that employee training was performed.\n\n2. You must implement the monitoring procedures and frequency that you have listed in your HACCP plan, to comply with 21 CFR 123.6(b), (c)(4). However, your firm did not follow monitoring and verification procedures for your Combined Molluscan Shellfish, Scombroid Fish and Pasteurized Crabmeat HACCP plans. Specifically,\n\na. The monitoring procedure at the storage critical control point (CCP) for your Scombroid fish lists checking the adequacy of ice “(b)(4)”. However, your firm operates (b)(4). According to your Daily Seafood Sanitation Reports on June 3, 6, 13, 17, 18, 20, 24, and 25, 2023 and July 4, 8, and 9, 2023, the adequacy of ice was (b)(4). On June 11 and July 1-3, 2023, the adequacy of ice was not checked at all. Furthermore, the monitoring procedures don’t include taking the internal temperatures of fish to ensure the critical limit is met. The monitoring procedures don’t require a representative number of containers to be examined and the approximate number of containers in the cooler.\n\nYour written response indicated that your HACCP plans are under review and will be revised. Additionally, your response indicated that employees were trained on proper monitoring procedures; however, a new HACCP plan hasn’t been implemented yet, nor was evidence provided to document employee training was performed. This response is inadequate in that corrective actions have not been taken or implemented. You also failed to offer a timeframe on when these revisions would be completed.\n\n3. You must take appropriate corrective actions when a deviation from a critical limit occurs, to comply with 21 CFR 123.7(a). However, your corrective actions were not appropriate to control your hazards of pathogenic bacteria growth, toxin formation and C. botulinum toxin formation when your cooler temperatures for the storage of Pasteurized Crabmeat and your shucked shellfish meat deviated from your listed critical limits of “Storage cooler temperature should not exceed (b)(4) for over (b)(4)” and “Storge cooler temperature not to exceed (b)(4)”, respectively.\n\nFurthermore, your trained Seafood HACCP employee reviewed your CMS records that revealed critical limit deviations and failed to evaluate the product or conduct any type of corrective actions.\n\nYour written response indicated that employees were trained on the importance of performing necessary corrective actions; however, you failed to provide evidence that employee training was performed.\n\n4. Your HACCP plans include corrective action plans that are not in accordance with 21 CFR 123.7(b) to ensure affected product is not entered into commerce and the cause of the deviation was corrected as required by 21 CFR 123.6(c)(5). Specifically,\n\na. The CCP of cooler storage of fresh shucked shellfish meat for you Combined Molluscan Shellfish and Pasteurized Crabmeat HACCP plans are inadequate to control Clostridium botulinum growth and toxin formation. Your HACCP plans do not list corrective actions on evaluating the cumulative time and the ambient cooler temperature exposures of the affected product, rejecting the lot or diverting to a non-food use.\n\nb. The CCP’s of receiving and Finished Product Storage in the Scombroid Fish HACCP plan are inadequate to control histamine formation. Taking the internal product temperature alone at receiving does not control the hazard. Additionally, waiting until the finished product storage cooler temperature is above (b)(4) for more than (b)(4), checking the adequacy of ice and product temperature does not control the hazard. Furthermore, the HACCP plan doesn’t document chilling, holding, rejecting or diverting the lot to non-food use.\n\nYour written response indicated that your HACCP plans are under review. This response is inadequate in that corrective actions have not been taken or implemented. Additionally, you failed to offer a timeframe on when these revisions would be completed.\n\n5. You must monitor sanitation conditions and practices during processing with sufficient frequency to ensure compliance with current good manufacturing practice requirements in 21 CFR 117, Subpart B (CGMPs) to comply with 21 CFR 123.11 (b). However, your firm did not monitor for the adequacy of key areas of sanitation (b)(4) on June 3, 9, 13, 17, 18, 20, 24, 25 and July 4, 8 and 9, 2023. Additionally, you failed to check the adequacy of any key areas of sanitation at all on June 11 and July 1-3, 2023.\n\nYour written response indicated that employees were trained to check and record sanitation conditions and practices (b)(4) per shift; however, you failed to provide evidence that employee training was performed or adequately completed “Daily Seafood CCP and Sanitation Report” forms.\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. You should take prompt action to address the violations noted in this letter. Failure to promptly address these violations may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so.\n\nIf you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. Please send your reply to the Food and Drug Administration, Attention: Allison Hunter, Compliance Officer, 550 Main Street, Suite 4-930, Cincinnati, Ohio 45202. If you prefer to send your response electronically, please email it to ORAHAFEAST5FirmResponses@fda.hhs.gov. If you have any questions regarding this letter, please contact Allison C. Hunter, Compliance Officer, at Allison.hunter@fda.hhs.gov or (513) 322-0629.\n\nSincerely,\n\n\u002FS\u002F\n\nSteven B. Barber\n\nDirector, Division V\n\nOffice of Human and Animal Foods Operations-East","Euro USA Inc","euro-usa-inc-666173-11222023","2026-08-18T06:42:28.994808+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feuro-usa-inc-666173-11222023","2026-10-26T08:08:36.767386+00:00","Warning Letter","Closed Out","2024-04-16","666173","Food & Beverages","2024-09-23","Division of Human and Animal Food Operations East V","Mr. Joseph O’Donnell","2026-08-20T00:10:33.528+00:00","VIA UNITED PARCEL SERVICE AND VIA E-MAIL","2023-11-22",{"id":35,"raw":36,"subject":41,"body_html":42,"body_text":43,"firm_name":44,"letter_id":45,"created_at":46,"fei_number":20,"letter_url":47,"updated_at":48,"action_type":23,"case_status":49,"posted_date":50,"marcs_cms_no":51,"product_type":52,"closeout_date":20,"issuing_office":40,"recipient_name":53,"body_fetched_at":54,"delivery_method":55,"recipient_title":20,"reference_number":20,"action_taken_date":56,"medical_device_id":20,"response_letter_date":20},348,[37,38,39,40,41,13,13,13],"\u003Ctime datetime=\"2026-02-03T05:00:00Z\">02\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-10T04:00:00Z\">09\u002F10\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feniva-usa-inc-706565-09102025\">Eniva USA, Inc.\u003C\u002Fa>","Human Foods Program","CGMP\u002FDietary Supplement\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Andrew J Baechler\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Eniva USA, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2700 Campus Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Plymouth\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55441-2601\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:andyb@eniva.com\"> andyb@eniva.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 10, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS #706565\u003C\u002Fp>\u003Cp>Dear Mr. Baechler:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility, located at 2700 Campus Dr., Plymouth, MN, from November 19, 2024, through January 13, 2025. Based on inspectional findings and review of product labels collected during the inspections, as well as review of your website, www.eniva.com, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection on January 13, 2025, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your response on February 5, 2025, and we address your response below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Adulterated Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection of your facility from November 19, 2024, through January 13, 2025, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause your Immune Support (previously called Cold Buster) and Ashwagandha Gummies dietary supplements to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] in that they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\u003C\u002Fp>\u003Cp>Your significant violations of the CGMP requirements are as follows:\u003C\u002Fp>\u003Cp>1) You failed to establish product specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplements, as required by 21 CFR 111.70(e). During the inspection, your Senior Quality Manager stated that your finished product specifications are maintained in the form of blank “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” documents. However, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” documents do not establish product specifications that confirm the identity, purity, strength, and composition of the finished batches of your Cold Buster (now Immune Support) and Ashwagandha Gummies dietary supplements. Specifically:\u003C\u002Fp>\u003Cul>\u003Cli>Your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” document for your Cold Buster (now Immune Support) lists appearance, color, odor, conductivity, pH, percent solids, and specific gravity as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” These factors do not constitute unique criteria that can confirm the identity of the Cold Buster product. Additionally, these factors do not—either alone or in conjunction—evaluate the purity, strength, and composition of this finished product.\u003C\u002Fli>\u003Cli>Your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” document for your Ashwaghanda Gummies lists appearance, color, odor, and water activity as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” These factors do not constitute unique criteria that can confirm the identity of the Ashwaghanda Gummies product. Additionally, these factors do not—either alone or in conjunction—evaluate the purity, strength, and composition of this finished product.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We have reviewed your response to the FDA Form 483, received February 5, 2025, and find it does not adequately address the violation. In your response, you stated that you plan to update finished product specification forms for the finished dietary supplement products you manufacture, including Immune Support and Ashwagandha Gummies. However, to date, you have not submitted any evidence of further corrective action.\u003C\u002Fp>\u003Cp>2) You failed to make and keep documentation of any material review and disposition decision and follow-up, as required by 21 CFR 111.140(b)(3). Specifically, your Senior Quality Manager stated that when “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” results had been encountered by your firm since your last inspection for incoming components and outgoing dietary supplements, you failed to document the investigation, findings, material review by quality, and the disposition of affected materials.\u003C\u002Fp>\u003Cp>We have reviewed your response to the FDA Form 483, received February 5, 2025, and find it does not adequately address the violation. In your response, you stated that you will review and update your SOP QS-009, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and proceed to document all investigations. However, to date, you have not submitted any evidence of corrective action.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>In addition to the above-mentioned violations, we also have the following comment:\u003C\u002Fp>\u003Cp>We conducted a case assessment and review of your firm’s response regarding observation 1, namely 21 CFR 114.83 for acid foods. Your response to this observation appears inadequate. We request the following be addressed by your firm:\u003C\u002Fp>\u003Cul>\u003Cli>Is management able to furnish the supporting documents from the University of Minnesota which support the conclusion that these products are acid foods?\u003C\u002Fli>\u003Cli>Has management made formulation changes to the following original four products: Vibe Original, Vibe 2.0, Vibe Apple and Vibe Kids?\u003C\u002Fli>\u003Cli>Has management fully evaluated the other products, not listed above, to determine if they are acidified or acid food products?\u003C\u002Fli>\u003Cli>Please provide a list of ingredients, pH for all ingredients, formulation, and finished product pH for the Vibe product for review. Does your firm add acid ingredients to shift the product pH? What is the pH of the product before acidulent is added?\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written reply should be directed to Rebecca Allen, Compliance Officer, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #706565 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD, MBA\u003Cbr>Acting Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nAndrew J Baechler\n\nRecipient Title\n\nCEO\n\nEniva USA, Inc.\n\n2700 Campus Dr.\n\nPlymouth, MN 55441-2601\n\nUnited States\n\nandyb@eniva.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nSeptember 10, 2025\nWARNING LETTER\nCMS #706565\nDear Mr. Baechler:\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your facility, located at 2700 Campus Dr., Plymouth, MN, from November 19, 2024, through January 13, 2025. Based on inspectional findings and review of product labels collected during the inspections, as well as review of your website, www.eniva.com, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\nAt the conclusion of the inspection on January 13, 2025, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your response on February 5, 2025, and we address your response below.\nAdulterated Dietary Supplements\nThe inspection of your facility from November 19, 2024, through January 13, 2025, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause your Immune Support (previously called Cold Buster) and Ashwagandha Gummies dietary supplements to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] in that they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\nYour significant violations of the CGMP requirements are as follows:\n1) You failed to establish product specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplements, as required by 21 CFR 111.70(e). During the inspection, your Senior Quality Manager stated that your finished product specifications are maintained in the form of blank “(b)(4)” documents. However, your “(b)(4)” documents do not establish product specifications that confirm the identity, purity, strength, and composition of the finished batches of your Cold Buster (now Immune Support) and Ashwagandha Gummies dietary supplements. Specifically:\nYour “(b)(4)” document for your Cold Buster (now Immune Support) lists appearance, color, odor, conductivity, pH, percent solids, and specific gravity as “(b)(4).” These factors do not constitute unique criteria that can confirm the identity of the Cold Buster product. Additionally, these factors do not—either alone or in conjunction—evaluate the purity, strength, and composition of this finished product.\nYour “(b)(4)” document for your Ashwaghanda Gummies lists appearance, color, odor, and water activity as “(b)(4).” These factors do not constitute unique criteria that can confirm the identity of the Ashwaghanda Gummies product. Additionally, these factors do not—either alone or in conjunction—evaluate the purity, strength, and composition of this finished product.\nWe have reviewed your response to the FDA Form 483, received February 5, 2025, and find it does not adequately address the violation. In your response, you stated that you plan to update finished product specification forms for the finished dietary supplement products you manufacture, including Immune Support and Ashwagandha Gummies. However, to date, you have not submitted any evidence of further corrective action.\n2) You failed to make and keep documentation of any material review and disposition decision and follow-up, as required by 21 CFR 111.140(b)(3). Specifically, your Senior Quality Manager stated that when “(b)(4)” results had been encountered by your firm since your last inspection for incoming components and outgoing dietary supplements, you failed to document the investigation, findings, material review by quality, and the disposition of affected materials.\nWe have reviewed your response to the FDA Form 483, received February 5, 2025, and find it does not adequately address the violation. In your response, you stated that you will review and update your SOP QS-009, “(b)(4),” and proceed to document all investigations. However, to date, you have not submitted any evidence of corrective action.\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nIn addition to the above-mentioned violations, we also have the following comment:\nWe conducted a case assessment and review of your firm’s response regarding observation 1, namely 21 CFR 114.83 for acid foods. Your response to this observation appears inadequate. We request the following be addressed by your firm:\nIs management able to furnish the supporting documents from the University of Minnesota which support the conclusion that these products are acid foods?\nHas management made formulation changes to the following original four products: Vibe Original, Vibe 2.0, Vibe Apple and Vibe Kids?\nHas management fully evaluated the other products, not listed above, to determine if they are acidified or acid food products?\nPlease provide a list of ingredients, pH for all ingredients, formulation, and finished product pH for the Vibe product for review. Does your firm add acid ingredients to shift the product pH? What is the pH of the product before acidulent is added?\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written reply should be directed to Rebecca Allen, Compliance Officer, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #706565 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD, MBA\nActing Director, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Eniva USA, Inc.","eniva-usa-inc-706565-09102025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feniva-usa-inc-706565-09102025","2026-10-26T08:08:35.579466+00:00","Issued","2026-02-03","706565","Dietary Supplements","Andrew J Baechler","2026-08-19T05:07:51.096+00:00","Via Email","2025-09-10",{"id":58,"raw":59,"subject":64,"body_html":65,"body_text":66,"firm_name":67,"letter_id":68,"created_at":69,"fei_number":20,"letter_url":70,"updated_at":71,"action_type":23,"case_status":49,"posted_date":72,"marcs_cms_no":73,"product_type":27,"closeout_date":20,"issuing_office":63,"recipient_name":74,"body_fetched_at":75,"delivery_method":76,"recipient_title":20,"reference_number":20,"action_taken_date":77,"medical_device_id":20,"response_letter_date":20},3288,[60,61,62,63,64,13,13,13],"\u003Ctime datetime=\"2021-06-29T13:20:00Z\">06\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-06-21T04:00:00Z\">06\u002F21\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fidc-usa-inc-613966-06212021\">IDC USA INC\u003C\u002Fa>","Division of Northeast Imports","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Hu Liu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>IDC USA INC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6619 18th Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Brooklyn\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11204-4315\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Northeast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 613966\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 21, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Hu Liu:\u003C\u002Fp>\n\n\u003Cp>On December 3, 2020, through February 24, 2021, the Food and Drug Administration conducted a remote Foreign Supplier Verification Program (FSVP) inspection of IDC USA Inc. located at 6619 18th Ave Brooklyn, NY 11204. We also conducted an inspection on February 26, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the inspection, we found that you were not in compliance with the requirements of 21 CFR part 1 subpart L for your dried longan and dried \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;dates imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dried fungus imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that during the most recent inspection you stated that you are \u003Cstrong>(b)(4)\u003C\u002Fstrong> and you provided our investigator with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, private laboratory analysis for shipments of dried \u003Cstrong>(b)(4)\u003C\u002Fstrong> dates and dried longan imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a supplier evaluation questionnaire completed by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a document stating that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is a qualified supplier from January 2020 through December 2021 dated January 15, 2020, and written assurances from some of your foreign suppliers, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>, stating that their processes and procedures provide at least the same level of public health protection as FDA food safety regulations. However, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> you provided show that your firm \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of both the initial FSVP inspection on February 26, 2019, and the follow-up inspection on February 24, 2021, our investigator provided you in each instance with a Form FDA 483a, FSVP Observations. We received your response to the initial inspection on March 10, 2019, which included documents related to dried mushrooms imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dried \u003Cstrong>(b)(4)\u003C\u002Fstrong> dates and herbal tea imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The documents included a “Supplier Evaluation Questionnaire” for \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as well as the hazard analysis and Hazard Analysis Critical Control Point (HACCP) plan for dried shrimp and dried shellfish imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;and the hazard analysis and HACCP plan for dried mushroom (dried fungus) imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also provided analytical reports for entries of dried mushroom, dried shrimp, and dried \u003Cstrong>(b)(4)\u003C\u002Fstrong> dates. We acknowledged your response on September 6, 2019 and provided you some additional guidance. In general, these documents could be used as part of your FSVP, but you did not document your review and assessment of these documents. To date, we have not received your response to the Form FDA 483a issued on February 24, 2021.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, your firm did not develop an FSVP for your dried longan and dried \u003Cstrong>(b)(4)\u003C\u002Fstrong> dates imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>2. You did not conduct a written hazard analysis for your dried fungus imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong> to determine whether there are any hazards requiring a control, as required by 21 CFR 1.504. We note that you may meet your requirement to conduct a hazard analysis, as required under 21 CFR 1.504(a), by reviewing and assessing your supplier’s hazard analysis and documenting your review and assessment of that hazard analysis (21 CFR 1.504(d)). The FSVP regulation also generally requires that you evaluate your foreign supplier’s performance (21 CFR 1.505) and conduct foreign supplier verification activities (21 CFR 1.506), among other requirements. With respect to your evaluation of a foreign supplier’s performance, you may rely on another entity’s evaluation, but that entity may not be the foreign supplier themselves, and you must document your review and assessment of the evaluation, as required under 21 CFR 1.505(d). In addition, you provided private laboratory analysis for shipments of dried \u003Cstrong>(b)(4)\u003C\u002Fstrong> dates imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dried longan imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. While sampling and testing of a food may be an appropriate supplier verification activity, the testing should be specific to the hazards being controlled, among other requirements (21 CFR 1.506).\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food products you import for which you appear to be in violation of section 805. We may place the foods you import from the identified foreign suppliers on detention without physical examination (DWPE) when you import these products. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct these violations. You should include in your response documentation and information that will assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Linda Ross, FDA Compliance Officer; Division of Northeast Imports: ORAOEIONEIMPORTSWLResponses@fda.hhs.gov. Please also cc (carbon copy) linda.ross@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Ross via email at linda.ross@fda.hhs.gov. Please reference CMS # 613966 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Anna Alexander\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of Northeast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Hu Liu\n\nRecipient Title\n\nPresident\n\nIDC USA INC\n\n6619 18th Ave\n\nBrooklyn, NY 11204-4315\n\nUnited States\n\nIssuing Office:\n\nDivision of Northeast Imports\n\nUnited States\n\nWARNING LETTER\n\nCMS # 613966\n\nJune 21, 2021\n\nDear Mr. Hu Liu:\n\nOn December 3, 2020, through February 24, 2021, the Food and Drug Administration conducted a remote Foreign Supplier Verification Program (FSVP) inspection of IDC USA Inc. located at 6619 18th Ave Brooklyn, NY 11204. We also conducted an inspection on February 26, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the inspection, we found that you were not in compliance with the requirements of 21 CFR part 1 subpart L for your dried longan and dried (b)(4) dates imported from (b)(4) located in (b)(4) and dried fungus imported from (b)(4) in (b)(4). Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nWe acknowledge that during the most recent inspection you stated that you are (b)(4) and you provided our investigator with (b)(4), private laboratory analysis for shipments of dried (b)(4) dates and dried longan imported from (b)(4), a supplier evaluation questionnaire completed by (b)(4), a document stating that (b)(4) is a qualified supplier from January 2020 through December 2021 dated January 15, 2020, and written assurances from some of your foreign suppliers, including (b)(4), stating that their processes and procedures provide at least the same level of public health protection as FDA food safety regulations. However, the (b)(4) you provided show that your firm (b)(4).\n\nAt the conclusion of both the initial FSVP inspection on February 26, 2019, and the follow-up inspection on February 24, 2021, our investigator provided you in each instance with a Form FDA 483a, FSVP Observations. We received your response to the initial inspection on March 10, 2019, which included documents related to dried mushrooms imported from (b)(4) located in (b)(4) and dried (b)(4) dates and herbal tea imported from (b)(4) located in (b)(4). The documents included a “Supplier Evaluation Questionnaire” for (b)(4) and (b)(4), as well as the hazard analysis and Hazard Analysis Critical Control Point (HACCP) plan for dried shrimp and dried shellfish imported from (b)(4) and the hazard analysis and HACCP plan for dried mushroom (dried fungus) imported from (b)(4). You also provided analytical reports for entries of dried mushroom, dried shrimp, and dried (b)(4) dates. We acknowledged your response on September 6, 2019 and provided you some additional guidance. In general, these documents could be used as part of your FSVP, but you did not document your review and assessment of these documents. To date, we have not received your response to the Form FDA 483a issued on February 24, 2021.\n\nYour significant violations of the FSVP regulation are as follows:\n\n1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, your firm did not develop an FSVP for your dried longan and dried (b)(4) dates imported from (b)(4) located in (b)(4).\n\n2. You did not conduct a written hazard analysis for your dried fungus imported from (b)(4) located in (b)(4) to determine whether there are any hazards requiring a control, as required by 21 CFR 1.504. We note that you may meet your requirement to conduct a hazard analysis, as required under 21 CFR 1.504(a), by reviewing and assessing your supplier’s hazard analysis and documenting your review and assessment of that hazard analysis (21 CFR 1.504(d)). The FSVP regulation also generally requires that you evaluate your foreign supplier’s performance (21 CFR 1.505) and conduct foreign supplier verification activities (21 CFR 1.506), among other requirements. With respect to your evaluation of a foreign supplier’s performance, you may rely on another entity’s evaluation, but that entity may not be the foreign supplier themselves, and you must document your review and assessment of the evaluation, as required under 21 CFR 1.505(d). In addition, you provided private laboratory analysis for shipments of dried (b)(4) dates imported from (b)(4) and dried longan imported from (b)(4). While sampling and testing of a food may be an appropriate supplier verification activity, the testing should be specific to the hazards being controlled, among other requirements (21 CFR 1.506).\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food products you import for which you appear to be in violation of section 805. We may place the foods you import from the identified foreign suppliers on detention without physical examination (DWPE) when you import these products. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act.\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct these violations. You should include in your response documentation and information that will assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Linda Ross, FDA Compliance Officer; Division of Northeast Imports: ORAOEIONEIMPORTSWLResponses@fda.hhs.gov. Please also cc (carbon copy) linda.ross@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Ross via email at linda.ross@fda.hhs.gov. Please reference CMS # 613966 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nAnna Alexander\n\nActing Program Division Director\n\nDivision of Northeast Imports","IDC USA INC","idc-usa-inc-613966-06212021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fidc-usa-inc-613966-06212021","2026-10-26T08:08:57.279135+00:00","2021-06-29","613966","Mr. Hu Liu","2026-08-20T03:02:45.492+00:00","VIA UNITED PARCEL SERVICE","2021-06-21",{"id":79,"raw":80,"subject":64,"body_html":85,"body_text":86,"firm_name":87,"letter_id":88,"created_at":69,"fei_number":20,"letter_url":89,"updated_at":90,"action_type":23,"case_status":49,"posted_date":91,"marcs_cms_no":92,"product_type":27,"closeout_date":20,"issuing_office":84,"recipient_name":93,"body_fetched_at":94,"delivery_method":95,"recipient_title":20,"reference_number":20,"action_taken_date":96,"medical_device_id":20,"response_letter_date":20},3361,[81,82,83,84,64,13,13,13],"\u003Ctime datetime=\"2021-05-11T13:20:00Z\">05\u002F11\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-04-30T04:00:00Z\">04\u002F30\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fj-l-usa-inc-613754-04302021\">J &amp; L USA Inc.\u003C\u002Fa>","Division of West Coast Imports","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Sam Sanwei Liang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>J &amp; L USA Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6541 E Washington Boulevard\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Commerce\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90040-1821\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of West Coast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 30, 2021\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 613754\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Liang:\u003C\u002Fp>\n\n\u003Cp>On January 19, 2021, the Food and Drug Administration conducted a Foreign Supplier Verification Program (FSVP) inspection of FSVP records that you submitted to FDA electronically for your firm J &amp; L USA Inc., located at 6541 E Washington Blvd., Commerce, CA 90040-1821. We also conducted an inspection on May 31, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the Foreign Supplier Verification Program (FSVP) implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During our inspections, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for Green Tea and Dried Bamboo Leaf imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>; Dried White Fungus imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, we found that you are still not in compliance with the requirements of 21 CFR Part 1 subpart L for the Rock Candy and Brown Candy in Pieces imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> from the previous inspection. Your firm did not have FSVPs for these food products. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of both the initial FSVP inspection on May 31, 2019 and the current inspection on January 19, 2021, our investigator provided you with Form FDA 483a, FSVP Observations. We have not received your response to either Form FDA 483a.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, your firm did not develop an FSVP for each of the following foods:\u003C\u002Fp>\n\n\u003Cp>a. Green Tea imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\nb. Dried Bamboo Leaf imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\nc. Dried White Fungus imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\nd. Rock Candy imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\ne. Brown Candy in Pieces imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The above violation is not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter adequately may lead to regulatory action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of Green Tea and Dried Bamboo Leaf imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>; Dried White Fungus imported from&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>; and Rock Candy and Brown Candy in Pieces imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> that appear to be in violation of section 805. We may place these foods you import from the identified foreign suppliers on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert #99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to address any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Nabeela J. Chaudhry, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Nabeela Chaudhry via email at nabeela.chaudhry@fda.hhs.gov. Please reference CMS #613754 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lawton W. Lum\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nSam Sanwei Liang\n\nRecipient Title\n\nGeneral Manager\n\nJ & L USA Inc.\n\n6541 E Washington Boulevard\n\nCommerce, CA 90040-1821\n\nUnited States\n\nIssuing Office:\n\nDivision of West Coast Imports\n\nUnited States\n\nWARNING LETTER\n\nApril 30, 2021\n\nRe: CMS # 613754\n\nDear Mr. Liang:\n\nOn January 19, 2021, the Food and Drug Administration conducted a Foreign Supplier Verification Program (FSVP) inspection of FSVP records that you submitted to FDA electronically for your firm J & L USA Inc., located at 6541 E Washington Blvd., Commerce, CA 90040-1821. We also conducted an inspection on May 31, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the Foreign Supplier Verification Program (FSVP) implementing regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring our inspections, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for Green Tea and Dried Bamboo Leaf imported from (b)(4); Dried White Fungus imported from (b)(4). Additionally, we found that you are still not in compliance with the requirements of 21 CFR Part 1 subpart L for the Rock Candy and Brown Candy in Pieces imported from (b)(4) from the previous inspection. Your firm did not have FSVPs for these food products. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of both the initial FSVP inspection on May 31, 2019 and the current inspection on January 19, 2021, our investigator provided you with Form FDA 483a, FSVP Observations. We have not received your response to either Form FDA 483a.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, your firm did not develop an FSVP for each of the following foods:\n\na. Green Tea imported from (b)(4), located in (b)(4)\n\nb. Dried Bamboo Leaf imported from (b)(4), located in (b)(4)\n\nc. Dried White Fungus imported from (b)(4), located in (b)(4)\n\nd. Rock Candy imported from (b)(4), located in (b)(4)\n\ne. Brown Candy in Pieces imported from (b)(4), located in (b)(4)\n\nThe above violation is not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter adequately may lead to regulatory action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of Green Tea and Dried Bamboo Leaf imported from (b)(4); Dried White Fungus imported from (b)(4); and Rock Candy and Brown Candy in Pieces imported from (b)(4) that appear to be in violation of section 805. We may place these foods you import from the identified foreign suppliers on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert #99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act.\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to address any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Nabeela J. Chaudhry, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Nabeela Chaudhry via email at nabeela.chaudhry@fda.hhs.gov. Please reference CMS #613754 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nLawton W. Lum\n\nActing Program Division Director\n\nDivision of West Coast Imports","J & L USA Inc.","j-l-usa-inc-613754-04302021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fj-l-usa-inc-613754-04302021","2026-10-26T08:09:02.006209+00:00","2021-05-11","613754","Sam Sanwei Liang","2026-08-20T03:08:54.946+00:00","United Parcel Service","2021-04-30",{"id":98,"raw":99,"subject":104,"body_html":105,"body_text":106,"firm_name":107,"letter_id":108,"created_at":46,"fei_number":20,"letter_url":109,"updated_at":110,"action_type":23,"case_status":49,"posted_date":111,"marcs_cms_no":112,"product_type":113,"closeout_date":20,"issuing_office":103,"recipient_name":114,"body_fetched_at":115,"delivery_method":116,"recipient_title":20,"reference_number":117,"action_taken_date":118,"medical_device_id":20,"response_letter_date":20},211,[100,101,102,103,104,13,13,13],"\u003Ctime datetime=\"2026-04-21T04:00:00Z\">04\u002F21\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-15T04:00:00Z\">04\u002F15\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpar-health-usa-llc-endo-usa-inc-722121-04152026\">Par Health USA, LLC &amp; Endo USA, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-68\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. John Caldwell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>VP Manufacturing Operations\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Par Health USA, LLC &amp; Endo USA, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>870 Parkdale Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Rochester\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>48307-1740\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-68\u003C\u002Fp>\u003Cp>April 15, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Caldwell:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, ENDO USA, Inc., FEI 1818977, at 870 Parkdale Road, Rochester, from October 6 to 20, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your November 10, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Design of Facility and Equipment\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm is a contract manufacturer of sterile injectable drug products produced primarily through aseptic processing including, but not limited to, products for \u003Cstrong>(b)(4)\u003C\u002Fstrong> use. \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your aseptic processing lines are described as “\u003Cstrong>(b)(4)\u003C\u002Fstrong> restricted access barrier systems.” However, \u003Cstrong>(b)(4)\u003C\u002Fstrong> of these processing lines \u003Cstrong>(b)(4)\u003C\u002Fstrong> are not restricted access barrier systems (RABS). They lacked fundamental RABS design elements, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, that are essential for reducing or eliminating direct gowned personnel intervention into the critical (ISO 5) area during batch manufacturing.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> are \u003Cstrong>(b)(4)\u003C\u002Fstrong> foundational elements of RABS design and control, minimizing contamination risk from the surrounding cleanroom environment. Without these basic features, your processing lines \u003Cstrong>(b)(4)\u003C\u002Fstrong> cannot be categorized as RABS.\u003C\u002Fp>\u003Cp>Additionally, your processing lines \u003Cstrong>(b)(4)\u003C\u002Fstrong> were designed as traditional aseptic filling lines surrounded by barrier \u003Cstrong>(b)(4)\u003C\u002Fstrong> under \u003Cstrong>(b)(4)\u003C\u002Fstrong> high efficiency particulate air (HEPA) systems. These processing lines required manually intensive operations during equipment setup and throughout routine production, and did not provide appropriate separation and protection of the ISO 5 areas. For example, we observed the following regarding these aseptic processing lines:\u003C\u002Fp>\u003Cul>\u003Cli>Excessive and high-risk manual interventions required during operations on your aseptic processing lines created unacceptable hazards to product sterility. For instance, barrier \u003Cstrong>(b)(4)\u003C\u002Fstrong> lines \u003Cstrong>(b)(4)\u003C\u002Fstrong> required hundreds of interventions, including numerous lubrications of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and conveyor belts with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, during the production of a batch.\u003C\u002Fli>\u003Cli>Product contact equipment on multiple lines was poorly protected or otherwise exposed to contamination hazards. For example:\u003Cbr>o Barrier \u003Cstrong>(b)(4)\u003C\u002Fstrong> on opposite sides of processing line \u003Cstrong>(b)(4)\u003C\u002Fstrong> remained \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the surrounding environment for almost \u003Cstrong>(b)(4)\u003C\u002Fstrong> during installation of the stopper bowl assembly.\u003Cbr>o \u003Cstrong>(b)(4)\u003C\u002Fstrong> manifold set up on line \u003Cstrong>(b)(4)\u003C\u002Fstrong> required personnel to break first pass air to the critical areas of the production line with their arms, head, and upper body, and lasted nearly \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>o The design of the stopper bowl component required personnel to break first pass air with \u003Cstrong>(b)(4)\u003C\u002Fstrong> and forearms during installation on production lines \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>o Product tubing extended above and over open vials and filling operations of line \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your aseptic processing cleanroom layout, filling equipment design, protection of ISO 5 areas, and the number and complexity of personnel interventions during setup and filling operations are deficient. These basic design deficiencies and manually intensive interventions affect multiple processing lines and compromise your ability to maintain aseptic conditions.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Environmental Monitoring\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You also failed to ensure adequate environmental monitoring (EM) of classified areas used for aseptic production of sterile injectable drug products. For example:\u003C\u002Fp>\u003Cul>\u003Cli>EM of critical filling equipment \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not ensure each of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> were periodically assessed for microbiological quality.\u003C\u002Fli>\u003Cli>Your EM program for ISO 5 non-viable particulate monitoring was deficient. You failed to demonstrate that your sample collection apparatus (using tubing \u003Cstrong>(b)(4)\u003C\u002Fstrong> long with \u003Cstrong>(b)(4)\u003C\u002Fstrong> bends) provides meaningful and representative samples.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cem>Inadequate Unidirectional Airflow\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The qualification of airflow in critical areas demonstrated further inadequacies in the suitability and design of aseptic processing lines \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Dynamic airflow studies demonstrated that airflow patterns failed to adequately protect the aseptic processing line, including exposed sterile product and product contact equipment, from significant contamination hazards.\u003C\u002Fp>\u003Cp>Your dynamic smoke studies did not demonstrate unidirectional airflow protection of the production line while barrier \u003Cstrong>(b)(4)\u003C\u002Fstrong> were \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The study showed air moving at a sharp angle toward \u003Cstrong>(b)(4)\u003C\u002Fstrong> vents, leaving critical areas of your aseptic processing line potentially unprotected.\u003C\u002Fp>\u003Cp>Furthermore, design flaws in production equipment led to poor aseptic practices and ergonomics that compromised unidirectional airflow. For example:\u003C\u002Fp>\u003Cul>\u003Cli>The \u003Cstrong>(b)(4)\u003C\u002Fstrong> assembly design required personnel to grip the \u003Cstrong>(b)(4)\u003C\u002Fstrong> with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, touching the critical portions of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> through which the \u003Cstrong>(b)(4)\u003C\u002Fstrong> during assembly.\u003C\u002Fli>\u003Cli>Personnel blocked first pass air to \u003Cstrong>(b)(4)\u003C\u002Fstrong> with their forearms and \u003Cstrong>(b)(4)\u003C\u002Fstrong> during installation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> assembly.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your response emphasizes aseptic processing controls measured by environmental and personnel monitoring recovery rates, numbers of media filled units produced, and sterility tests performed. Furthermore, in your response you also commit to reconfiguring line \u003Cstrong>(b)(4)\u003C\u002Fstrong>, tightening EM specifications for ISO 5 non-viable particulate monitoring to account for tubing length, eliminating the need for \u003Cstrong>(b)(4)\u003C\u002Fstrong> lubrication, and ensuring all \u003Cstrong>(b)(4)\u003C\u002Fstrong> are monitored. You also acknowledge the high-risk aseptic line setup activities and have implemented improvements including maintaining \u003Cstrong>(b)(4)\u003C\u002Fstrong> protection of equipment for a longer period, changing sequence of setup activities, and improving operator ergonomics.\u003C\u002Fp>\u003Cp>Your response is inadequate as the retrospective review does not overcome fundamental design flaws. Rather than implementing more extensive changes to the aseptic processing operation, you are attempting to partially mitigate significant aseptic processing line hazards. Overall, your response fails to address how you will ensure adequate aseptic processing operations and collect meaningful data to support your aseptic processes.\u003C\u002Fp>\u003Cp>We acknowledge that you also have temporarily suspended manufacture and release of aseptically filled product from all \u003Cstrong>(b)(4)\u003C\u002Fstrong> production lines pending a third-party consultant review.\u003C\u002Fp>\u003Cp>Your aseptic manufacturing processes should be designed, and operations executed, to prevent contamination hazards to your sterile product. Flaws in the design of cleanrooms and aseptic processing lines, or improper execution of aseptic operations, can promote influx of contamination into the critical processing area.\u003C\u002Fp>\u003Cp>Your firm’s response also includes evaluation of retrospective sterility testing data. It should be noted that a sterility test, while a critical quality control for aseptically processed products that purport to be sterile, cannot be solely relied upon as justification to release drug product batches. The test is only the last in a series of design provisions and controls intended to protect the consumer from distribution of an unsafe batch.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:\u003Cbr>o All human interactions within the ISO 5 area (e.g., risk reduction or elimination of manual interventions wherever possible)\u003Cbr>o Equipment suitability (e.g., reliability, capability, placement, ergonomics)\u003Cbr>o Air quality in the ISO 5 area and surrounding room\u003Cbr>o Facility layout\u003Cbr>o Material transfers\u003Cbr>o Personnel and material\u002Fprocess flow throughout all rooms used to conduct and support sterile operations\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible, comprehensive improvements to be made to aseptic processing operation design (e.g., separation, automation) and control, and explain how this corrective action and preventive action (CAPA) plan will systematically remediate your aseptic processing operation.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Process Simulation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your media fills failed to accurately simulate aseptic manufacturing operations.\u003C\u002Fp>\u003Cp>Your data reported maximum aseptic intervention counts per batch of over \u003Cstrong>(b)(4)\u003C\u002Fstrong> for line \u003Cstrong>(b)(4)\u003C\u002Fstrong> and nearing \u003Cstrong>(b)(4)\u003C\u002Fstrong> for line \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Approximately 30% of these interventions involved lubricating productions lines with \u003Cstrong>(b)(4)\u003C\u002Fstrong> due to persistent challenges with the proper functioning and movement of vials during processing. However, the number of worst-case interventions performed during routine batch manufacturing was significantly reduced in your media fill simulations. Additionally, you made the total number of units in your media fill simulations substantially smaller than some of your aseptically produced batch sizes.\u003C\u002Fp>\u003Cp>In your response, you commit to including the maximum number of interventions during a media fill and to addressing the need for lubricating production lines. However, you fail to address media fill batch sizes. Given the manually intensive nature of your processes and fundamental design flaws, your media fills should reflect the worst-case number and type of interventions. When the potential for contamination is higher, as it is with the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> processing lines surrounded by barrier \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the number of units in a media fill should be the same as, or approach, the maximum production batch size. If a media fill program fails to incorporate contamination risk factors and closely simulate actual drug product exposure, the state of process control and assurance of sterility cannot be accurately assessed. Furthermore, your aseptic processing lines require an inordinate number of interventions and necessitate fundamental design remediations. Notably, media fills cannot justify unsuitable manufacturing lines and processing conditions.\u003C\u002Fp>\u003Cp>\u003Cem>Poor Aseptic Technique and Cleanroom Behavior\u003C\u002Fem>\u003C\u002Fp>\u003Cp>We observed poor aseptic practices that were due, in part, to inadequate line design. In addition, our investigators observed operators failing to follow your written procedures during production operations on aseptic processing lines \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These deviations included, but were not limited to:\u003C\u002Fp>\u003Cul>\u003Cli>Reaching over the \u003Cstrong>(b)(4)\u003C\u002Fstrong> processing line, open vials, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, sleeves, head, and shoulders to perform line interventions.\u003C\u002Fli>\u003Cli>Inappropriate transfer of \u003Cstrong>(b)(4)\u003C\u002Fstrong> stoppers to the production line. For example:\u003Cbr>o Failure to follow procedures to disinfect the stopper bag during transfer to the production room.\u003Cbr>o Cutting open the stopper bag and exposing stoppers to the ISO 7 environment prior to emptying the contents into the ISO 5 production line.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your response includes changes to procedures with applicable training for aseptic processing operators. However, your response fails to sufficiently acknowledge design flaws (e.g., equipment ergonomic flaws that affect operator performance), excessive need for manual manipulations, insufficiency of barrier protection to provide adequate separation from surrounding areas, and other fundamental issues.\u003C\u002Fp>\u003Cp>See FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Your systematic plan to assure adherence to appropriate aseptic practices, cleanroom behavior, and written procedures including, not but limited to, an independent assessment of the following with accompanying CAPA:\u003Cbr>o suitability of actual practices based on extensive retrospective review and prospective observation of aseptic processing operations\u003Cbr>o deficiencies in production management oversight and identification of specific improvements to ensure effective and routine supervisory oversight for all batches\u003Cbr>o frequency and depth of quality unit oversight (e.g., audit, ad hoc, daily interactions) of aseptic processing and its support operations\u003Cbr>o adequacy of written procedures\u003Cbr>o evaluation of how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\u003C\u002Fli>\u003Cli>A comprehensive independent review of your process simulation (e.g., media fill) program to ensure appropriate simulations of worst-case conditions in commercial manufacturing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your visual inspection program was inadequate to ensure your sterile injectable drug products were essentially free of visible particulates. For example,\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Personnel Capabilities\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your probability of detection of particulates using \u003Cstrong>(b)(4)\u003C\u002Fstrong> visual inspection was inadequate. You conducted Knapp studies for \u003Cstrong>(b)(4)\u003C\u002Fstrong>-mL and \u003Cstrong>(b)(4)\u003C\u002Fstrong>-mL vials and demonstrated that personnel were often not able to achieve a probability of detection of 70% for certain critical particulates larger than 150 microns (e.g., dark fibers, light fibers, glass, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Procedures and Particle Characterization\u003C\u002Fem>\u003C\u002Fp>\u003Cul>\u003Cli>You incorrectly categorized critical defects as major and subsequently approved products that passed acceptable quality limits (AQL) testing. After completion of our inspection, you submitted Field Alert Reports for \u003Cstrong>(b)(4)\u003C\u002Fstrong> different products manufactured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> different product lines where major particulates were recategorized as critical with subsequent AQL failures.\u003C\u002Fli>\u003Cli>Your written procedures allowed multiple re-inspections for visual particulates, and you acknowledged that up to \u003Cstrong>(b)(4)\u003C\u002Fstrong> re-inspections may be performed in support of batch release.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Furthermore, since 2023 you failed to conduct thorough investigations of trends in product quality glass defects that adequately remediate your visual inspection program and include adequate support for your product quality impact conclusions.\u003C\u002Fp>\u003Cp>Your response included further details pertaining to a September 2023 deviation for adhered glass defect from a specific vial vendor. Your clarification further acknowledges that your visual inspection program did not adequately assess this defect type.\u003C\u002Fp>\u003Cp>Although you stopped using the glass supplier and determined the defect had no impact on your batches, your investigation failed to assess the full scope, including the number of vials procured and used, and the impact on your entire product portfolio.\u003C\u002Fp>\u003Cp>Additionally, adhered glass defects represent a recurring problem inadequately detected by your visual inspection program and not properly addressed through CAPA. For example, you produced \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> in July and August 2024. Your quality unit approved them for release, but later you identified internal adhered glass defects in these batches.\u003C\u002Fp>\u003Cp>Further, you initiated CAPA 11768 following our inspection to assess 28 AQL failures related to visual inspection. You identified six as needing CAPA improvement.\u003C\u002Fp>\u003Cp>Your response acknowledges serious deficiencies in your visual inspection program, as you have halted all visual inspection activities and hired a third-party consultant to completely remediate your process. You also commit to retrospective evaluation of all deviations for the previous three years, re-inspection of all retained samples for batches associated with adhered glass AQL failures, procedural changes to particle characterization\u002Fclassification including performing retrospective trending and review, enhanced personnel training, and limiting the number of re-inspections to \u003Cstrong>(b)(4)\u003C\u002Fstrong> prior to batch disposition. Your response omits an assessment of products currently in commerce. You continue to lack assurance that distributed products are essentially free of visible particulate matter.\u003C\u002Fp>\u003Cp>Visual detection of particulates is a probabilistic process that depends on, among other things, ensuring that visible particulates can be reproducibly detected by trained personnel with appropriate visual acuity. At a minimum, personnel should reliably be capable of detecting particulates of 150 microns or greater at a 70% probability of detection. Furthermore, written procedures governing 100% inspections for visual particulates should clearly define the number of times re-inspection may be performed. You should limit and justify re-inspections. Generally, FDA does not recommend more than one re-inspection in an attempt to release a batch with atypical defect levels\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan for your visual inspection program to ensure compliance with CGMP. The remediation plan should incorporate:\u003Cbr>o Implementing enhancements to your 100% visible inspection program\u003Cbr>o Ensuring adequate methods and personnel qualifications to reproducibly detect visible particulates including particulates which historically have been identified in your operation.\u003Cbr>o For drug products that are difficult to inspect (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>, suspension products, \u003Cstrong>(b)(4)\u003C\u002Fstrong> containers), implementing destructive testing or other advanced technologies (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) as appropriate, with statistically significant sample sizes to test for critical defects.\u003Cbr>o Incorporating product-specific knowledge, process experience, deviation investigation analysis, recall\u002Fcomplaint data, and quality risk management to improve the visual inspection program.\u003C\u002Fli>\u003Cli>Your associated remediations to your visual inspection program including any newly established written procedures and methods. Include a summary of the review and recommendations made by your independent consultant.\u003C\u002Fli>\u003Cli>Provide an assessment of changes implemented to your component supplier qualification program, visual inspection qualification practices, and CAPA to prevent visible particulates (e.g., glass) from contaminating your injectable drug products.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, action level results (out of limits), and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Visible Particulate Contamination\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We encourage the use of suitable automated visual inspection for particulates to augment the \u003Cstrong>(b)(4)\u003C\u002Fstrong> visual inspection program. Automated methods should be rigorously studied, and qualified, to assess their capability and robustness under various conditions, machine settings, container-closure sizes, defect types, product characteristic, and other variables. In addition, any use of automated particulate inspection as an adjunct method does not supplant the need for \u003Cstrong>(b)(4)\u003C\u002Fstrong> visual inspection for various other attributes (e.g., cracks; myriad defects of container or closure; \u003Cstrong>(b)(4)\u003C\u002Fstrong> issues, volume, atypical \u003Cstrong>(b)(4)\u003C\u002Fstrong> or other appearance defects).\u003C\u002Fp>\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1818977 and ATTN: Matthew R. Dionne, Pharm.D., Compliance Officer.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>___________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See FDA’s draft guidance document Inspection of Injectable Products for Visible Particulates to help you meet the CGMP requirements pertaining to visible particulate inspections of sterile injectable drug products at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F154868\u002Fdownload.\u003Cbr>\u003Cbr>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-68\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. John Caldwell\n\nRecipient Title\n\nVP Manufacturing Operations\n\nPar Health USA, LLC & Endo USA, Inc.\n\n870 Parkdale Road\n\nRochester, MI 48307-1740\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-68\nApril 15, 2026\nDear Mr. Caldwell:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, ENDO USA, Inc., FEI 1818977, at 870 Parkdale Road, Rochester, from October 6 to 20, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your November 10, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).\nInadequate Design of Facility and Equipment\nYour firm is a contract manufacturer of sterile injectable drug products produced primarily through aseptic processing including, but not limited to, products for (b)(4) use. (b)(4) of your aseptic processing lines are described as “(b)(4) restricted access barrier systems.” However, (b)(4) of these processing lines (b)(4) are not restricted access barrier systems (RABS). They lacked fundamental RABS design elements, such as (b)(4), that are essential for reducing or eliminating direct gowned personnel intervention into the critical (ISO 5) area during batch manufacturing.\n(b)(4) are (b)(4) foundational elements of RABS design and control, minimizing contamination risk from the surrounding cleanroom environment. Without these basic features, your processing lines (b)(4) cannot be categorized as RABS.\nAdditionally, your processing lines (b)(4) were designed as traditional aseptic filling lines surrounded by barrier (b)(4) under (b)(4) high efficiency particulate air (HEPA) systems. These processing lines required manually intensive operations during equipment setup and throughout routine production, and did not provide appropriate separation and protection of the ISO 5 areas. For example, we observed the following regarding these aseptic processing lines:\nExcessive and high-risk manual interventions required during operations on your aseptic processing lines created unacceptable hazards to product sterility. For instance, barrier (b)(4) lines (b)(4) required hundreds of interventions, including numerous lubrications of (b)(4) and conveyor belts with (b)(4), during the production of a batch.\nProduct contact equipment on multiple lines was poorly protected or otherwise exposed to contamination hazards. For example:\no Barrier (b)(4) on opposite sides of processing line (b)(4) remained (b)(4) to the surrounding environment for almost (b)(4) during installation of the stopper bowl assembly.\no (b)(4) manifold set up on line (b)(4) required personnel to break first pass air to the critical areas of the production line with their arms, head, and upper body, and lasted nearly (b)(4).\no The design of the stopper bowl component required personnel to break first pass air with (b)(4) and forearms during installation on production lines (b)(4).\no Product tubing extended above and over open vials and filling operations of line (b)(4).\nYour aseptic processing cleanroom layout, filling equipment design, protection of ISO 5 areas, and the number and complexity of personnel interventions during setup and filling operations are deficient. These basic design deficiencies and manually intensive interventions affect multiple processing lines and compromise your ability to maintain aseptic conditions.\nInadequate Environmental Monitoring\nYou also failed to ensure adequate environmental monitoring (EM) of classified areas used for aseptic production of sterile injectable drug products. For example:\nEM of critical filling equipment (b)(4) did not ensure each of the (b)(4) were periodically assessed for microbiological quality.\nYour EM program for ISO 5 non-viable particulate monitoring was deficient. You failed to demonstrate that your sample collection apparatus (using tubing (b)(4) long with (b)(4) bends) provides meaningful and representative samples.\nInadequate Unidirectional Airflow\nThe qualification of airflow in critical areas demonstrated further inadequacies in the suitability and design of aseptic processing lines (b)(4). Dynamic airflow studies demonstrated that airflow patterns failed to adequately protect the aseptic processing line, including exposed sterile product and product contact equipment, from significant contamination hazards.\nYour dynamic smoke studies did not demonstrate unidirectional airflow protection of the production line while barrier (b)(4) were (b)(4). The study showed air moving at a sharp angle toward (b)(4) vents, leaving critical areas of your aseptic processing line potentially unprotected.\nFurthermore, design flaws in production equipment led to poor aseptic practices and ergonomics that compromised unidirectional airflow. For example:\nThe (b)(4) assembly design required personnel to grip the (b)(4) with (b)(4), touching the critical portions of the (b)(4) through which the (b)(4) during assembly.\nPersonnel blocked first pass air to (b)(4) with their forearms and (b)(4) during installation of the (b)(4) assembly.\nYour response emphasizes aseptic processing controls measured by environmental and personnel monitoring recovery rates, numbers of media filled units produced, and sterility tests performed. Furthermore, in your response you also commit to reconfiguring line (b)(4), tightening EM specifications for ISO 5 non-viable particulate monitoring to account for tubing length, eliminating the need for (b)(4) lubrication, and ensuring all (b)(4) are monitored. You also acknowledge the high-risk aseptic line setup activities and have implemented improvements including maintaining (b)(4) protection of equipment for a longer period, changing sequence of setup activities, and improving operator ergonomics.\nYour response is inadequate as the retrospective review does not overcome fundamental design flaws. Rather than implementing more extensive changes to the aseptic processing operation, you are attempting to partially mitigate significant aseptic processing line hazards. Overall, your response fails to address how you will ensure adequate aseptic processing operations and collect meaningful data to support your aseptic processes.\nWe acknowledge that you also have temporarily suspended manufacture and release of aseptically filled product from all (b)(4) production lines pending a third-party consultant review.\nYour aseptic manufacturing processes should be designed, and operations executed, to prevent contamination hazards to your sterile product. Flaws in the design of cleanrooms and aseptic processing lines, or improper execution of aseptic operations, can promote influx of contamination into the critical processing area.\nYour firm’s response also includes evaluation of retrospective sterility testing data. It should be noted that a sterility test, while a critical quality control for aseptically processed products that purport to be sterile, cannot be solely relied upon as justification to release drug product batches. The test is only the last in a series of design provisions and controls intended to protect the consumer from distribution of an unsafe batch.\nIn response to this letter, provide:\nComprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:\no All human interactions within the ISO 5 area (e.g., risk reduction or elimination of manual interventions wherever possible)\no Equipment suitability (e.g., reliability, capability, placement, ergonomics)\no Air quality in the ISO 5 area and surrounding room\no Facility layout\no Material transfers\no Personnel and material\u002Fprocess flow throughout all rooms used to conduct and support sterile operations\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible, comprehensive improvements to be made to aseptic processing operation design (e.g., separation, automation) and control, and explain how this corrective action and preventive action (CAPA) plan will systematically remediate your aseptic processing operation.\n2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\nInadequate Process Simulation\nYour media fills failed to accurately simulate aseptic manufacturing operations.\nYour data reported maximum aseptic intervention counts per batch of over (b)(4) for line (b)(4) and nearing (b)(4) for line (b)(4). Approximately 30% of these interventions involved lubricating productions lines with (b)(4) due to persistent challenges with the proper functioning and movement of vials during processing. However, the number of worst-case interventions performed during routine batch manufacturing was significantly reduced in your media fill simulations. Additionally, you made the total number of units in your media fill simulations substantially smaller than some of your aseptically produced batch sizes.\nIn your response, you commit to including the maximum number of interventions during a media fill and to addressing the need for lubricating production lines. However, you fail to address media fill batch sizes. Given the manually intensive nature of your processes and fundamental design flaws, your media fills should reflect the worst-case number and type of interventions. When the potential for contamination is higher, as it is with the use of (b)(4) processing lines surrounded by barrier (b)(4), the number of units in a media fill should be the same as, or approach, the maximum production batch size. If a media fill program fails to incorporate contamination risk factors and closely simulate actual drug product exposure, the state of process control and assurance of sterility cannot be accurately assessed. Furthermore, your aseptic processing lines require an inordinate number of interventions and necessitate fundamental design remediations. Notably, media fills cannot justify unsuitable manufacturing lines and processing conditions.\nPoor Aseptic Technique and Cleanroom Behavior\nWe observed poor aseptic practices that were due, in part, to inadequate line design. In addition, our investigators observed operators failing to follow your written procedures during production operations on aseptic processing lines (b)(4). These deviations included, but were not limited to:\nReaching over the (b)(4) processing line, open vials, and (b)(4) equipment with (b)(4), sleeves, head, and shoulders to perform line interventions.\nInappropriate transfer of (b)(4) stoppers to the production line. For example:\no Failure to follow procedures to disinfect the stopper bag during transfer to the production room.\no Cutting open the stopper bag and exposing stoppers to the ISO 7 environment prior to emptying the contents into the ISO 5 production line.\nYour response includes changes to procedures with applicable training for aseptic processing operators. However, your response fails to sufficiently acknowledge design flaws (e.g., equipment ergonomic flaws that affect operator performance), excessive need for manual manipulations, insufficiency of barrier protection to provide adequate separation from surrounding areas, and other fundamental issues.\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nIn response to this letter, provide:\nYour systematic plan to assure adherence to appropriate aseptic practices, cleanroom behavior, and written procedures including, not but limited to, an independent assessment of the following with accompanying CAPA:\no suitability of actual practices based on extensive retrospective review and prospective observation of aseptic processing operations\no deficiencies in production management oversight and identification of specific improvements to ensure effective and routine supervisory oversight for all batches\no frequency and depth of quality unit oversight (e.g., audit, ad hoc, daily interactions) of aseptic processing and its support operations\no adequacy of written procedures\no evaluation of how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\nA comprehensive independent review of your process simulation (e.g., media fill) program to ensure appropriate simulations of worst-case conditions in commercial manufacturing.\n3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\nYour visual inspection program was inadequate to ensure your sterile injectable drug products were essentially free of visible particulates. For example,\nInadequate Personnel Capabilities\nYour probability of detection of particulates using (b)(4) visual inspection was inadequate. You conducted Knapp studies for (b)(4)-mL and (b)(4)-mL vials and demonstrated that personnel were often not able to achieve a probability of detection of 70% for certain critical particulates larger than 150 microns (e.g., dark fibers, light fibers, glass, and (b)(4)).\nInadequate Procedures and Particle Characterization\nYou incorrectly categorized critical defects as major and subsequently approved products that passed acceptable quality limits (AQL) testing. After completion of our inspection, you submitted Field Alert Reports for (b)(4) different products manufactured on (b)(4) different product lines where major particulates were recategorized as critical with subsequent AQL failures.\nYour written procedures allowed multiple re-inspections for visual particulates, and you acknowledged that up to (b)(4) re-inspections may be performed in support of batch release.\nFurthermore, since 2023 you failed to conduct thorough investigations of trends in product quality glass defects that adequately remediate your visual inspection program and include adequate support for your product quality impact conclusions.\nYour response included further details pertaining to a September 2023 deviation for adhered glass defect from a specific vial vendor. Your clarification further acknowledges that your visual inspection program did not adequately assess this defect type.\nAlthough you stopped using the glass supplier and determined the defect had no impact on your batches, your investigation failed to assess the full scope, including the number of vials procured and used, and the impact on your entire product portfolio.\nAdditionally, adhered glass defects represent a recurring problem inadequately detected by your visual inspection program and not properly addressed through CAPA. For example, you produced (b)(4) batches of (b)(4) in July and August 2024. Your quality unit approved them for release, but later you identified internal adhered glass defects in these batches.\nFurther, you initiated CAPA 11768 following our inspection to assess 28 AQL failures related to visual inspection. You identified six as needing CAPA improvement.\nYour response acknowledges serious deficiencies in your visual inspection program, as you have halted all visual inspection activities and hired a third-party consultant to completely remediate your process. You also commit to retrospective evaluation of all deviations for the previous three years, re-inspection of all retained samples for batches associated with adhered glass AQL failures, procedural changes to particle characterization\u002Fclassification including performing retrospective trending and review, enhanced personnel training, and limiting the number of re-inspections to (b)(4) prior to batch disposition. Your response omits an assessment of products currently in commerce. You continue to lack assurance that distributed products are essentially free of visible particulate matter.\nVisual detection of particulates is a probabilistic process that depends on, among other things, ensuring that visible particulates can be reproducibly detected by trained personnel with appropriate visual acuity. At a minimum, personnel should reliably be capable of detecting particulates of 150 microns or greater at a 70% probability of detection. Furthermore, written procedures governing 100% inspections for visual particulates should clearly define the number of times re-inspection may be performed. You should limit and justify re-inspections. Generally, FDA does not recommend more than one re-inspection in an attempt to release a batch with atypical defect levels1.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan for your visual inspection program to ensure compliance with CGMP. The remediation plan should incorporate:\no Implementing enhancements to your 100% visible inspection program\no Ensuring adequate methods and personnel qualifications to reproducibly detect visible particulates including particulates which historically have been identified in your operation.\no For drug products that are difficult to inspect (e.g., (b)(4), suspension products, (b)(4) containers), implementing destructive testing or other advanced technologies (e.g., (b)(4)) as appropriate, with statistically significant sample sizes to test for critical defects.\no Incorporating product-specific knowledge, process experience, deviation investigation analysis, recall\u002Fcomplaint data, and quality risk management to improve the visual inspection program.\nYour associated remediations to your visual inspection program including any newly established written procedures and methods. Include a summary of the review and recommendations made by your independent consultant.\nProvide an assessment of changes implemented to your component supplier qualification program, visual inspection qualification practices, and CAPA to prevent visible particulates (e.g., glass) from contaminating your injectable drug products.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, action level results (out of limits), and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nVisible Particulate Contamination\nWe encourage the use of suitable automated visual inspection for particulates to augment the (b)(4) visual inspection program. Automated methods should be rigorously studied, and qualified, to assess their capability and robustness under various conditions, machine settings, container-closure sizes, defect types, product characteristic, and other variables. In addition, any use of automated particulate inspection as an adjunct method does not supplant the need for (b)(4) visual inspection for various other attributes (e.g., cracks; myriad defects of container or closure; (b)(4) issues, volume, atypical (b)(4) or other appearance defects).\nIneffective Quality System\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days2. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1818977 and ATTN: Matthew R. Dionne, Pharm.D., Compliance Officer.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n___________________________\n1 See FDA’s draft guidance document Inspection of Injectable Products for Visible Particulates to help you meet the CGMP requirements pertaining to visible particulate inspections of sterile injectable drug products at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F154868\u002Fdownload.\n\n2 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Par Health USA, LLC & Endo USA, Inc.","par-health-usa-llc-endo-usa-inc-722121-04152026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpar-health-usa-llc-endo-usa-inc-722121-04152026","2026-10-26T08:09:40.22559+00:00","2026-04-21","722121","Drugs","Mr. John Caldwell","2026-08-19T04:46:32.187+00:00","VIA UPS","320-26-68","2026-04-15",5,{"510k":121,"classification":122,"enforcement":123,"event":124,"event_backfill":125,"pma":126,"warning_letter":127},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-19T04:00:36.695+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]